Danaher Corporation vs Marqeta Inc — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while Marqeta Inc trades at $18.11 (market cap $1.82B). The key difference: Danaher Corporation is far larger — about 84× Marqeta Inc's market cap, and Danaher Corporation pays a 0.74% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Marqeta Inc for 44 Days on average.
| DHR | MQ | |
|---|---|---|
Market Cap | $152.87B | $1.82B |
Volume | 5,228,698 | 1,126,466 |
Sector | Health | Technology |
52-Week High | $242.05 | $20.32 |
52-Week Low | $161.91 | $15.04 |
Typical Hold Time | 69 Days | 44 Days |
Enterprise Value | $175.08B | $1.13B |
Dividend Yield | 0.74% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
Marqeta (MQ) trades at $17.44, up 2.23% today, showing strong momentum after beating earnings expectations for three consecutive quarters. The stock displays a bullish technical outlook with positive moving average signals, though valuation metrics remain elevated with a P/E of 193.83. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight ongoing business expansion despite mixed analyst sentiment.
MQ presents a high-risk, high-reward opportunity with improving fundamentals but premium valuation. Revenue growth has recovered from 2024 lows, and cash flow turned positive in 2025. However, the stock trades above most analyst targets, and contract renewals in Q3 2026 create near-term uncertainty. Investors should weigh growth potential against valuation concerns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →